Case Report: Diagnostic pitfall and biomarker-guided therapy in CD20-negative Epstein–Barr virus-positive diffuse large B-cell lymphoma - Report - MDSpire
Clinical Report: Challenges in Diagnosis and Biomarker-Driven Treatment of CD20-Negative EBV+ DLBCL
Overview
This case study discusses a rare instance of CD20-negative Epstein–Barr virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL, NOS) and the complexities involved in its diagnosis and treatment. Integrated immunophenotypic and molecular analyses were crucial in establishing the diagnosis.
Background
EBV+ DLBCL, NOS is an aggressive lymphoma subtype characterized by the presence of Epstein–Barr virus within tumor cells. The absence of CD20 expression complicates both diagnosis and treatment, as it limits the use of anti-CD20 therapies and necessitates a broader differential diagnosis.
Data Highlights
No numerical or trial data provided in the source material.
Key Findings
CD20-negative EBV+ DLBCL, NOS is a rare subtype, comprising less than 1% of DLBCL cases.
Initial misdiagnosis as peripheral T-cell lymphoma occurred due to the absence of pan-B-cell markers.
Comprehensive immunophenotyping and molecular analysis were essential for accurate diagnosis.
Treatment involved CD30-targeted therapy and PD-1 blockade.
Further evaluation of CD20-independent treatment strategies is necessary for high-risk patients.
Clinical Implications
The case emphasizes the importance of thorough diagnostic evaluation in atypical lymphoma presentations, particularly in cases lacking CD20 expression.
Conclusion
This case illustrates the diagnostic challenges and treatment complexities associated with CD20-negative EBV+ DLBCL, NOS.
